- Home
- ARCO vs AZTA Comparison
ARCO vs AZTA Comparison
Compare ARCO & AZTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARCO
- AZTA
- Stock Information
- Founded
- ARCO 2007
- AZTA 1978
- Country
- ARCO Uruguay
- AZTA United States
- Employees
- ARCO N/A
- AZTA N/A
- Industry
- ARCO Restaurants
- AZTA Industrial Machinery/Components
- Sector
- ARCO Consumer Discretionary
- AZTA Technology
- Exchange
- ARCO Nasdaq
- AZTA Nasdaq
- Market Cap
- ARCO 2.1B
- AZTA 2.2B
- IPO Year
- ARCO 2011
- AZTA 1995
- Fundamental
- Price
- ARCO $8.33
- AZTA $45.53
- Analyst Decision
- ARCO Strong Buy
- AZTA Buy
- Analyst Count
- ARCO 2
- AZTA 5
- Target Price
- ARCO $13.50
- AZTA $63.60
- AVG Volume (30 Days)
- ARCO 1.1M
- AZTA 640.8K
- Earning Date
- ARCO 11-13-2024
- AZTA 11-12-2024
- Dividend Yield
- ARCO 2.87%
- AZTA N/A
- EPS Growth
- ARCO N/A
- AZTA N/A
- EPS
- ARCO 0.69
- AZTA N/A
- Revenue
- ARCO $4,501,397,000.00
- AZTA $656,323,000.00
- Revenue This Year
- ARCO $5.50
- AZTA $8.47
- Revenue Next Year
- ARCO $8.03
- AZTA $6.72
- P/E Ratio
- ARCO $12.35
- AZTA N/A
- Revenue Growth
- ARCO 7.82
- AZTA N/A
- 52 Week Low
- ARCO $8.07
- AZTA $38.82
- 52 Week High
- ARCO $13.20
- AZTA $69.16
- Technical
- Relative Strength Index (RSI)
- ARCO 38.55
- AZTA 55.17
- Support Level
- ARCO $8.07
- AZTA $38.82
- Resistance Level
- ARCO $8.87
- AZTA $50.81
- Average True Range (ATR)
- ARCO 0.28
- AZTA 2.55
- MACD
- ARCO -0.01
- AZTA 0.15
- Stochastic Oscillator
- ARCO 31.48
- AZTA 55.96
About ARCO Arcos Dorados Holdings Inc. Shares
Arcos Dorados Holdings Inc operates McDonald's-branded restaurants in approximately 20 countries and territories in Latin America and the Caribbean. It functions through two sources which include company-operated restaurants and franchised restaurants segment. Their menu includes hamburgers, McNuggets, salad, sandwiches, french fries and others.
About AZTA Azenta Inc.
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has two reportable segments that are Life Sciences Products and Life Sciences Services. It generates a substantial part of its revenue from its Life Sciences Services segment.